Terminated PHASE3 INTERVENTIONAL 5-arm NCT01111539

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions Major Depressive Disorder (MDD)

Interventions Aripiprazole Blinded capsule Escitalopram

Updated 9 times since 2017 Last updated: Sep 28, 2021 Started: Jul 13, 2010 Primary completion: Sep 20, 2011 Completion: Sep 20, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern.

Other terminated trials from Otsuka Pharmaceutical Development & Commercialization, Inc.

More terminations from Otsuka Pharmaceutical Development & Commercialization, Inc.

Other Major Depressive Disorder (MDD) trials with similar outcome

Browse all Major Depressive Disorder (MDD) trials

This PHASE3 trial investigates Major Depressive Disorder (MDD) and is currently terminated or withdrawn. Otsuka Pharmaceutical Development & Commercialization, Inc. leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Nov 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 4 earlier versions

Jan 2021 — Nov 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Albuquerque, United States , Berlin, Germany , Boston, United States , Brown Deer, United States , Cary, United States , Catania, Italy , Cerritos, United States , Changhua, Taiwan , Chicago, United States and 45 more locations